Fulcrum Therapeutics Inc (FULC) Stock Price, Quote & News - Mboum

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 651 8851

Website: www.fulcrumtx.com

Address:

26 Landsdowne Street, Cambridge, United States

GeriRaderstorf441 Aug. 1 at 6:28 PM

0 · Reply

edvquye Aug. 1 at 5:37 PM

$FULC in here

0 · Reply

alfafc Jul. 30 at 4:52 PM

0 · Reply

JarvisFlow Jul. 30 at 2:27 PM

RBC Capital updates rating for Fulcrum Therapeutics ( $FULC ) to Sector Perform, target set at 4 → 5.

0 · Reply

Dkll303 Jul. 30 at 12:22 PM

$AGIO $FULC Good olé HC WAINWRIGHT…sucking in investors to FULC …hahahaha .. Still at it …copy cat of LUTNICK- Cantor Fitz and his pathetic “ outperforms “ that DIE and never go any where …AGIO

0 · Reply

Quantumup Jul. 30 at 12:10 PM

H.C. Wainwright yesterday⬆️ $FULC to Buy-$12 from Neutral-$4. $PFE $VRTX $QURE SGMO $AGIO CRSP BLUE - CG H.C. Wainwright said, "Today's 12mg dataset from Fulcrum's PIONEER Phase 1b trial builds meaningfully on prior mechanistic and early clinical observations, offering a tangible glimpse into the translational potential of HbF induction in sickle cell disease (SCD). We view the absolute increase in fetal hemoglobin (HbF), combined with improvements in key hematologic and hemolytic parameters, as validation of pociredir's ability to recapitulate the protective biology observed in hereditary persistence of fetal hemoglobin (HPFH). This matters clinically because patients with HPFH exhibit far fewer vaso-occlusive complications despite possessing the same ß-globin mutation. H.C. Wainwright additionally said:

0 · Reply

d_risk Jul. 30 at 4:30 AM

$FULC - Fulcrum Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors FULC’s 10-Q reveals heightened risks from ongoing operating losses, Phase 3 failure-driven R&D cuts, clinical and regulatory uncertainties, intensified IP and commercialization challenges, new tax and pricing pressures, expanded compliance and cybersecurity risks, and concentrated ownership with anti-takeover measures. #Biotechnology #FinancialRisk #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/FULC/10-Q/2025-07-29

0 · Reply

LynnLopez996 Jul. 29 at 7:53 PM

0 · Reply

MaryButler201 Jul. 29 at 7:48 PM

0 · Reply

DanielLazenby397 Jul. 29 at 7:36 PM

0 · Reply

Latest News on FULC

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Jul 29, 2025, 6:48 AM EDT - 3 days ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 29, 2025, 6:45 AM EDT - 3 days ago

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Jul 28, 2025, 4:01 PM EDT - 4 days ago

Fulcrum Therapeutics to Present Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2025, 4:30 PM EDT - 21 days ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

May 29, 2025, 4:10 PM EDT - 2 months ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

May 29, 2025, 8:30 AM EDT - 2 months ago

Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Fulcrum Therapeutics to Participate in Upcoming May Conferences

May 8, 2025, 4:05 PM EDT - 3 months ago

Fulcrum Therapeutics to Participate in Upcoming May Conferences

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

May 1, 2025, 1:55 PM EDT - 3 months ago

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

May 1, 2025, 7:00 AM EDT - 3 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Apr 24, 2025, 8:00 AM EDT - 3 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 4:05 PM EST - 5 months ago

Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 10:58 PM EST - 5 months ago

Fulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call Transcript

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Feb 25, 2025, 7:00 AM EST - 5 months ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Feb 18, 2025, 4:05 PM EST - 5 months ago

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ET

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 6, 2025, 4:05 PM EST - 6 months ago

Fulcrum Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Nov 26, 2024, 4:05 PM EST - 8 months ago

Fulcrum Therapeutics to Participate in Upcoming December Conferences

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:48 PM EST - 9 months ago

Fulcrum Therapeutics, Inc. (FULC) Q3 2024 Earnings Call Transcript

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Nov 12, 2024, 4:05 PM EST - 9 months ago

Fulcrum Therapeutics to Participate in the Stifel Healthcare Conference

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

Nov 6, 2024, 8:00 AM EST - 9 months ago

Fulcrum Therapeutics to Host Third Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, November 13, 2024 at 8:00 a.m. ET

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Oct 7, 2024, 2:03 PM EDT - 10 months ago

FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Oct 2, 2024, 6:30 PM EDT - 10 months ago

Investors Are Invited To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Oct 1, 2024, 6:15 PM EDT - 10 months ago

Fulcrum Therapeutics, Inc. Is Being Investigated For Violating Securities Laws And The Schall Law Firm Urges Shareholder Participation

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

Sep 30, 2024, 8:00 PM EDT - 10 months ago

Investors Are Encouraged To Join The Schall Law Firm In An Inquiry Into Fulcrum Therapeutics Inc For Possible Securities Fraud

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Sep 28, 2024, 8:00 PM EDT - 10 months ago

The Schall Law Firm Is Looking Into Whether Fulcrum Therapeutics Inc Committed Securities Fraud And Impacted Investors Should Reach Out

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Sep 27, 2024, 6:30 PM EDT - 11 months ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Fulcrum Therapeutics, Inc. For Violating Securities Laws

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out

Sep 27, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out

Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand

Sep 26, 2024, 6:40 PM EDT - 11 months ago

Fulcrum Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Investors To Lend A Hand

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation

Sep 26, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Sep 25, 2024, 10:00 AM EDT - 11 months ago

Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Fulcrum Therapeutics Inc May Have Defrauded The Public And Affected Investors Should Join The Schall Law Firm's Inquiry

Sep 24, 2024, 6:00 PM EDT - 11 months ago

Fulcrum Therapeutics Inc May Have Defrauded The Public And Affected Investors Should Join The Schall Law Firm's Inquiry

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation

Sep 24, 2024, 10:00 AM EDT - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation

GeriRaderstorf441 Aug. 1 at 6:28 PM

0 · Reply

edvquye Aug. 1 at 5:37 PM

$FULC in here

0 · Reply

alfafc Jul. 30 at 4:52 PM

0 · Reply

JarvisFlow Jul. 30 at 2:27 PM

RBC Capital updates rating for Fulcrum Therapeutics ( $FULC ) to Sector Perform, target set at 4 → 5.

0 · Reply

Dkll303 Jul. 30 at 12:22 PM

$AGIO $FULC Good olé HC WAINWRIGHT…sucking in investors to FULC …hahahaha .. Still at it …copy cat of LUTNICK- Cantor Fitz and his pathetic “ outperforms “ that DIE and never go any where …AGIO

0 · Reply

Quantumup Jul. 30 at 12:10 PM

H.C. Wainwright yesterday⬆️ $FULC to Buy-$12 from Neutral-$4. $PFE $VRTX $QURE SGMO $AGIO CRSP BLUE - CG H.C. Wainwright said, "Today's 12mg dataset from Fulcrum's PIONEER Phase 1b trial builds meaningfully on prior mechanistic and early clinical observations, offering a tangible glimpse into the translational potential of HbF induction in sickle cell disease (SCD). We view the absolute increase in fetal hemoglobin (HbF), combined with improvements in key hematologic and hemolytic parameters, as validation of pociredir's ability to recapitulate the protective biology observed in hereditary persistence of fetal hemoglobin (HPFH). This matters clinically because patients with HPFH exhibit far fewer vaso-occlusive complications despite possessing the same ß-globin mutation. H.C. Wainwright additionally said:

0 · Reply

d_risk Jul. 30 at 4:30 AM

$FULC - Fulcrum Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors FULC’s 10-Q reveals heightened risks from ongoing operating losses, Phase 3 failure-driven R&D cuts, clinical and regulatory uncertainties, intensified IP and commercialization challenges, new tax and pricing pressures, expanded compliance and cybersecurity risks, and concentrated ownership with anti-takeover measures. #Biotechnology #FinancialRisk #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/FULC/10-Q/2025-07-29

0 · Reply

LynnLopez996 Jul. 29 at 7:53 PM

0 · Reply

MaryButler201 Jul. 29 at 7:48 PM

0 · Reply

DanielLazenby397 Jul. 29 at 7:36 PM

0 · Reply

LynnLopez996 Jul. 29 at 7:16 PM

0 · Reply

MaryButler201 Jul. 29 at 7:00 PM

0 · Reply

MaryKohl657 Jul. 29 at 6:24 PM

0 · Reply

MaryRoland830 Jul. 29 at 5:45 PM

0 · Reply

GeriRaderstorf441 Jul. 29 at 5:32 PM

0 · Reply

DavidGeorge1008 Jul. 29 at 5:14 PM

0 · Reply

EdnaZmolek1032 Jul. 29 at 4:59 PM

0 · Reply

LynnLopez996 Jul. 29 at 4:47 PM

0 · Reply

alfafc Jul. 29 at 3:39 PM

0 · Reply

_www_larval_com_ Jul. 29 at 2:42 PM

$FULC just stumbled -4% lower to -7% (~5Mv) moments ago, 08/15 options, follow for more volatility.

0 · Reply

biochirp Jul. 29 at 2:14 PM

$FULC guys the data was actually good

0 · Reply